Abstract:We investigated whether screening by whole genome sequencing (WGS) in unselected newborns provides more information of potentially curable or treatable medical conditions than routine newborn screening (NBS). We demonstrated that compared with routine NBS, WGS produced fewer false positive results and identified more actionable pathogenic or likely pathogenic variants in the selective 246 genes. Previously, WGS has been used to identify mutated genes in newborn children with a suspected disease.1 However, sequencing of apparently healthy newborns has remained controversial due to technical concerns and ethical issues.2 In this study, 321 non-pre-selected newborns from a cohort of pregnant women in Qingdao, China were recruited (Table 1). DNA from 303 umbilical cord blood samples and 18 umbilical cords was extracted for 40X WGS. For data interpretation, we selected 251 genes associated with 59 Mendelian disorders, 164 primary immunodeficiency diseases (PIDs) and five pharmacogenetic (PGx) genes, following the guidelines by the Recommended Uniform Screening Panel (RUSP), the International Union of Immunologic Societies (IUIS) Expert Committee for Primary Immunodeficiency, the Dutch Pharmacogenetics Working Group (DPWG), and the Clinical Pharmacogenetics Implementation Consortium (CPIC).3-5 Sequencing protocol, data analysis pipeline, and criteria for sequence variants interpretation following the ACMG/AMP guidelines are described in the Supporting Information. The WGS results were compared with NBS results, including the mandatory checks of hearing impairment and four metabolic diseases, the metabolic testing of 48 inherited metabolic diseases (IMDs), and the genetic screening for 20 hearing loss loci incorporated into the local NBS program in China.6, 7 Among the analysed DNA samples of 321 newborns, the average sequencing depth was 47.42X (28.84X–82.90X) and the average coverage was 99.48% (99.01%–99.89%) (Figure 1A). For the 59 Mendelian disorders, a total of 131 pathogenic or likely pathogenic (P/LP) mutations and 5 pathogenic copy number variations were detected in 107 of the 321 newborns (33.33%), corresponding to 106 carriers of 28 diseases and 1 patient with phenylketonuria (PKU) (Figure 1B and Table 2). The 25.23% of newborns (n = 81) carried one P/LP mutations, and 7.17% and 0.93% of newborns (n = 23 and n = 3) carried two or three P/LP mutations, respectively. Hearing loss, methylmalonic acidemia (MMA), primary congenital hypothyroidism (CH), and PKU were diseases with the most carriers, while GJB2 (28/321, 8.72%), MMACHC (11/321, 3.43%), DUOX2 (10/321, 3.12%), PAH (8/321, 2.49%) and SLC26A4 (8/321, 2.49%) were the top five genes with the highest carrier frequencies of P/LP mutations (Table 2). For the 164 PIDs, 9 heterozygous P/LP variants in 6 genes were identified in 9 newborns (2.80%), all in a heterozygous state (Table 2). Four newborns were shown to carry heterozygous variant of unknown significance (VUS) in the gene SLC25A13 (c.2T>C, p.M1T), which was predicted as start loss and likely affecting the initiator methionine of the SLC25A13 mRNA. Two newborns carried a VUS in ASS1(c.-4C>T, p.?). Although these VUSs were not included in the final report to the participants, follow-up of the children with VUSs will be conducted till 3 years of age. Sanger sequencing confirmed 143 out of 145 mutations identified by WGS, resulting in an accuracy of 98.62%. Carriers of SMN1 mutations were validated by multiplex ligation-dependent probe amplification and real-time quantitative PCR, showing that five out of the six predicted carriers were true. Of the 321 newborns, 312 (97.20%) had the results of 48 IMDs screening and genetic hearing loss screening on 20 loci, which identified one newborn with PKU and one infant with increased blood level of isovalerylcarnitine (Table 1). In addition, 18 carriers harbouring 20 pathogenic mutations causing hearing impairment were detected by genetic hearting loss screening, albeit all 321 children passed the physical hearing screening at hospital (Supporting Information). The newborn WGS also identified the PKU case and 18 hearing loss carriers (Figure 2A). However, the child with increased level of isovalerylcarnitine was confirmed to be a carrier of 3-methylcrotonyl-CoA carboxylase deficiency by WGS. In addition, WGS identified two infants carrying compound heterozygous P/LP variants in GJB2 (Figure 3) and four children carrying pathogenic mutations in MT-RNR1 (c1095T > C), suggesting an increased risk of late-onset deafness or drug-induced hearing loss, respectively. Although currently non-symptomatic, the two newborns with GJB2 variants were scheduled to undergo hearing tests every 6 months, and the four newborns with the m.1095T mutation in MT-RNR1 were advised to avoid using aminoglycosides. Interestingly, we observed that 313 newborns (97.51%) carried at least one actionable PGx variant (Figure 1C). This result is in line with a European 44 000 biobank participants study, where 99.8% of the participants had a genotype associated with increased risks to at least one medication.8 Furthermore, we found three common PGx variants in the Qingdao cohort, CYP2D6*10 (48.60%), NUDT15*3 (13.08%) and UGT1A1*6 (21.18%) (Figure 2B and Table 3), that showed significant frequency differences as compared to East Asian populations (p < 0.05). An important aspect when screening for disorders in a given population is the use of a matched control database as variants can be highly specific for a given ethnic group.9 Most databases published to date are based on individuals of European descent and many populations have limited or poor representation. Limitations of the current study are the small sample size and restricted metabolic tests. A large-scale NBS effort is needed to validate our findings and fully investigate the treatable or curable medical conditions in newborns. The technical challenge of newborn WGS is to screen genes with high homology due to the misalignment of short-read sequencing. Therefore, the customized pipeline is needed to improve the accuracy and sensitivity of SNVs at genes with high-level homology. Albeit the present cost and turnaround time of WGS is several times more than the present NBS methods, in the forseeable future the pitfalls of WGS cost and turnaround time will likely facilitate the application of newborn WGS in NBS programs. In our study, selective identification of genomic data, where therapeutic options are available, did not violate the Wilson–Jungner criteria10. Our work provides a basis for future research on expanding screening genes and diseases in newborn screening program. Given adequate cost-effectiveness, WGS should be considered in future newborn screening programs. Further discussion of the interpretation accuracy and ethical use of genomic information needs to take place on a global scale. We appreciate the participation of the volunteers and their families. Without their support, this work would not have been possible. This work was also supported by the China National GeneBank (CNGB). This study was funded by the National Natural Science Foundation of China (No.31800765), the Shenzhen Municipal Government of China (JCY20170817145047361) and the Guangdong Provincial Key Laboratory of Genome Read and Write (No. 2017B030301011). The authors declare no conflict of interest. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Abstract:Prenatal testing (NIPT) has been widely used in clinical screening for foetal chromosomal imbalances.1 Although the same NIPT data may be used to identify maternal copy number variants (CNVs),2 very limited information on CNVs in the DMD gene is available for large-scale populations. Here, we developed a new strategy for prenatal screening of CNVs in the DMD gene using NIPT data. Using this strategy, we evaluated the feasibility of using NIPT data to detect maternal CNVs in the DMD gene in a large cohort of 135,047 pregnant women. In addition, the carrier rate as well as the spectrum and types of maternal CNVs in the DMD gene were assessed. In this study, we implemented a self-developed method for detecting maternal CNVs. We reanalysed 135,047 NIPT samples collected from Nanjing Maternity and Child Health Care Hospital and Suzhou Municipal Hospital between January 2017 and December 2021 to identify maternal CNVs in the DMD gene (Figure S1). A total of 224 maternal CNVs in the DMD gene were identified (Table S1). Among these 201 CNVs (177 exonic and 24 intronic) validated by multiplex ligation-dependent probe amplification (MLPA), 128 true-positive exonic CNVs were successfully confirmed (Figure 1), including 48 CNVs (37.5%) with refined exons (Figure S2 and Table S2) and 5 large pathogenic/likely pathogenic CNVs (involving other genes in addition to DMD), which were confirmed by chromosomal microarray analysis (CMA) (Figure S3 and Table S3). Overall, the positive predictive value (PPV) of our method for all maternal exonic CNVs was 72.32% (128/177). The PPV for both deletions and duplications was influenced by the size of the exonic CNVs and reached a plateau at sizes of ≥300–1000 kb and ≥1000 kb, respectively (Table 1). Of these 128 true-positive maternal exonic CNVs, 64 were classified as pathogenic/likely pathogenic, 40 as variants of uncertain significance (VUS), and 24 as likely benign (Figure 2A and Table 2, Table S4). Among the 64 pathogenic/likely pathogenic CNVs, there were 33 different maternal CNVs in the DMD gene, 12 of which were recurrent CNVs. These recurrent CNVs occurred most commonly in exons 48–51, followed by exons 51–52, exons 45–55, and exons 49–51. Using data from the Leiden Open Variation Database,3 we further predicted the potential phenotypes for the 64 pathogenic/likely pathogenic maternal CNVs (Figure 2B and Table 2). Overall, 15.63% (10/64) of maternal CNVs detected in the DMD gene correlated with the DMD phenotype, 17.19% (11/64) correlated with the likely DMD phenotype, 14.06% (9/64) correlated with the likely BMD phenotype, 42.19% (27/64) correlated with the variable phenotype, and 10.94% (7/64) correlated with the underdetermined phenotype. For the 64 women with pathogenic/likely pathogenic variants, further testing was performed for 45 offspring. Overall, 40.00% (18/45) of the offspring inherited true-positive maternal CNVs from their mothers, including 11 male offspring and 7 female offspring (Figure 1). With a 1:1 male-to-female birth ratio, approximately 1.63% (11/67,523.5) of male offspring could be theoretically prenatally diagnosed and managed by our method. Among the 11 male offspring, 7 were successfully followed up, aged 8 months to 5 years (Table S5). The serum creatine kinase (CK) value in 71.43% (5/7) of these male offspring was elevated (reference 50–310 U/L). In Case M058, we identified a typical out-of-frame deletion (exons 48–50), which was classified as pathogenic and transmitted to the male offspring (Figure S4 and Table S5). Although the son manifested as phenotypically normal at 1 year old, a high serum CK level (12,416.8 U/L) suggested the possibility of DMD, which is consistent with our phenotype prediction result (likely DMD). Approximately one-third of individuals with DMD gene variants exhibit neurodevelopmental disorders, with speech delay and learning difficulties being common.4 In Case M010, a rare out-of-frame deletion (exons 2–9) was detected and transmitted to the male offspring (Figure S4 and Table S5). At two and a half years old, the son showed normal motor development with a normal serum creatine kinase (CK) level (125.4 U/L) but presented delayed speech development (echolalia and slurred speech) and slight behaviour and social problems. To date, this variant has only been reported in a pedigree of monozygotic male twins, in which one manifested autism spectrum disorder and the other presented learning difficulties.5 Our study provides further evidence that the deletion of exons 2–9 in the DMD gene could be associated with neurodevelopmental disorders rather than DMD/BMD. More relevant studies as well as long-term follow-up studies are essential to confirm this finding. Recent studies in other populations have reported carrier frequencies for DMD gene variants, including Belgium (1/2612),2 the United States (1/717),6 and Israel (1/1046).7 Our study extends this knowledge to the Chinese population, revealing an overall carrier frequency of 1/2110 (64/135,047), comparable to that of the Belgian cohort but varying from those of the United States and Israel cohorts. The possible reasons for these differences could be differences in methodologies, the potential influences of race and ethnicity, and different rules of pathogenicity interpretation for variants. Notably, we reported a total of 33 different pathogenic/likely pathogenic maternal CNVs in the DMD gene and calculated the carrier frequency for each CNV based on a large general population of reproductive-age women in China (Table 2), addressing a crucial gap in information regarding the carrier frequency and spectrum of maternal CNVs in the DMD gene in the Chinese population. Our datasets provide indispensable information for genetic counselling and can inform policy decisions for DMD/BMD screening worldwide. In summary, we developed a new strategy for prenatal screening of CNVs in the DMD gene based on NIPT data. Using the largest population to date, our study illustrates the spectrum and types of maternal CNVs in the DMD gene. Without any additional investment, the new strategy indicated potential clinical significance for maternal CNV detection, which is a natural application expansion for NIPT. Lijie Song, Ting Wang, Ping Hu, and Zhengfeng Xu designed the study. Ting Wang, Ping Hu, Xiaojuan Wu, and Ying Xue collected data. Yan Wang, Lulu Meng, Ran Zhou, Jianxin Tan, Dingyuan Ma, Yuguo Wang, Zhu Jiang, and Binbin Shao performed data analysis. Yan Wang, Lulu Meng, Quanze He, and Jingyu Zhao interpreted the data. Yan Wang and Yan Sun generated the bioinformatics workflow. Zhihong Qiao, Zhonghua Wang, Linlin Fan, and Yunmei Chen performed the statistical analyses. Yan Wang, Yan Sun, Lulu Meng, Quanze He, and Jingyu Zhao drafted the manuscript. Lijie Song, Ting Wang, Ping Hu, and Zhengfeng Xu revised the manuscript. All authors read and approved the final manuscript. This study was supported by the National Key R&D Program of China (No. 2022YFC2703400 to Xu, No. 2022YFC2703400 and No. 2021YFC1005301 to Hu.), the National Natural Science Foundation of China (No. 81971398, 82371862), Jiangsu Province Capability Improvement Project through Science, Technology and Education Jiangsu Provincial Medical Key Discipline (No. ZDXK202211), the Primary Research and Development Plan of Jiangsu Province (BE2022736), and Jiangsu Maternal and Children health care key discipline (FXK202142). The funding body played no role in the design of this study and collection, analysis, and interpretation of data and writing of the manuscript. The authors declare no conflicts of interest. National Key R&D Program of China (No. 2022YFC2703400 to Xu, No. 2022YFC2703400 and No. 2021YFC1005301 to Hu.), the National Natural Science Foundation of China (No. 81971398, 82371862), Jiangsu Province Capability Improvement Project through Science, Technology and Education Jiangsu Provincial Medical Key Discipline (No. ZDXK202211), the Primary Research and Development Plan of Jiangsu Province (BE2022736), and Jiangsu Maternal and Children health care key discipline (FXK202142). This study was approved by the Institutional Review Board of Nanjing Maternity and Child Health Care Hospital (2021KY-069), the Institutional Review Board of BGI (BGI-IRB 22020) and Suzhou Municipal Hospital (K-2022-001-H01) in accordance with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all the study participants at the time of providing samples, and individual data was de-identified. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

A Pilot Study of Assessing Whole Genome Sequencing in Newborn Screening in Unselected Children in China

A Multicenter Prospective Study of Next-Generation Sequencing-Based Newborn Screening for Monogenic Genetic Diseases in China

Application of a Next-Generation Sequencing (NGS) Panel in Newborn Screening Efficiently Identifies Inborn Disorders of Neonates

Secondary Genomic Findings in the 2020 China Neonatal Genomes Project Participants

Comprehensive Preimplantation Genetic Testing by Massively Parallel Sequencing

Genetic Identification of Pathogenic Variations of the DMD Gene: a Retrospective Study from 10,481 Neonatal Patients Based on Next-Generation Sequencing Data

Newborn screening with targeted sequencing: a multicenter investigation and a pilot clinical study in China

A pilot study of expanded newborn screening for 573 genes related to severe inherited disorders in China: results from 1,127 newborns

Diagnostic and Clinical Utility of Whole Genome Sequencing in a Cohort of Undiagnosed Chinese Families with Rare Diseases

Pilot Study of Expanded Newborn Screening for 573 Genes Related to Severe Diseases in China: Results from 1173 Newborns

[A prospective study of genetic screening of 2 060 neonates by high-throughput sequencing]

Genomic Sequencing As a First-Tier Screening Test and Outcomes of Newborn Screening.

A genome sequencing system for universal newborn screening, diagnosis, and precision medicine for severe genetic diseases

Targeted exome sequencing strategy (NeoEXOME) for Chinese newborns using a pilot study with 3423 neonates

Next-generation sequencing based newborn screening and comparative analysis with MS/MS

A New Strategy for Prenatal Genetic Screening of Copy Number Variations in the DMD Gene: A Large Cohort Study Based on NIPT Analysis

Expanded Newborn Screening Using Genome Sequencing for Early Actionable Conditions

Application of Next-Generation Sequencing for Genetic Diagnosis in Neonatal Intensive Care Units: Results of a Multicenter Study in China

Medical Exome As a First-Line Diagnostic Test in the Neonatal Intensive Care Unit: Experience in a Large Broad Cohort of 4,124 Neonates with Minimal Clinical Selection in China

A review of consensus statements, practice resources, standards and guidelines for clinical applications of next-generation sequencing technologies in the United States

Utility of Whole Genome Sequencing for Population Screening of Deafness-Related Genetic Variants and Cytomegalovirus Infection in Newborns